Edwards Lifesciences Co. (NYSE:EW) Shares Sold by Wealthcare Advisory Partners LLC

Wealthcare Advisory Partners LLC reduced its stake in shares of Edwards Lifesciences Co. (NYSE:EW) by 10.3% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 7,340 shares of the medical research company’s stock after selling 841 shares during the period. Wealthcare Advisory Partners LLC’s holdings in Edwards Lifesciences were worth $543,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in EW. FSA Wealth Management LLC purchased a new stake in Edwards Lifesciences during the third quarter worth $30,000. Prospera Private Wealth LLC purchased a new stake in shares of Edwards Lifesciences during the 3rd quarter worth about $32,000. Avior Wealth Management LLC grew its position in shares of Edwards Lifesciences by 138.7% during the 3rd quarter. Avior Wealth Management LLC now owns 530 shares of the medical research company’s stock valued at $35,000 after acquiring an additional 308 shares during the period. Peoples Bank KS acquired a new position in Edwards Lifesciences in the 3rd quarter worth about $40,000. Finally, JFS Wealth Advisors LLC boosted its position in Edwards Lifesciences by 31.1% during the third quarter. JFS Wealth Advisors LLC now owns 700 shares of the medical research company’s stock worth $46,000 after purchasing an additional 166 shares in the last quarter. 79.46% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research firms recently issued reports on EW. Morgan Stanley reissued an “equal weight” rating and issued a $70.00 price target on shares of Edwards Lifesciences in a research note on Friday, October 11th. Piper Sandler cut their target price on shares of Edwards Lifesciences from $73.00 to $70.00 and set a “neutral” rating for the company in a research note on Friday, October 25th. The Goldman Sachs Group upped their price target on shares of Edwards Lifesciences from $81.00 to $90.00 and gave the stock a “buy” rating in a research report on Thursday, December 5th. Stifel Nicolaus lifted their price objective on Edwards Lifesciences from $70.00 to $75.00 and gave the stock a “hold” rating in a report on Thursday, December 5th. Finally, JPMorgan Chase & Co. increased their target price on Edwards Lifesciences from $72.00 to $78.00 and gave the company a “neutral” rating in a report on Friday, October 25th. One investment analyst has rated the stock with a sell rating, fifteen have issued a hold rating and eleven have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $78.48.

Insider Activity

In related news, VP Donald E. Bobo, Jr. sold 5,000 shares of Edwards Lifesciences stock in a transaction on Wednesday, November 13th. The stock was sold at an average price of $65.57, for a total transaction of $327,850.00. Following the completion of the sale, the vice president now owns 46,936 shares of the company’s stock, valued at approximately $3,077,593.52. This trade represents a 9.63 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Daniel J. Lippis sold 500 shares of the business’s stock in a transaction that occurred on Thursday, January 16th. The shares were sold at an average price of $68.76, for a total value of $34,380.00. Following the completion of the sale, the vice president now directly owns 23,189 shares of the company’s stock, valued at approximately $1,594,475.64. The trade was a 2.11 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 33,000 shares of company stock worth $2,195,180. Insiders own 1.27% of the company’s stock.

Edwards Lifesciences Price Performance

NYSE EW opened at $69.77 on Tuesday. The company has a 50-day moving average price of $72.06 and a two-hundred day moving average price of $71.18. Edwards Lifesciences Co. has a 52 week low of $58.93 and a 52 week high of $96.12. The stock has a market cap of $41.15 billion, a price-to-earnings ratio of 10.07, a price-to-earnings-growth ratio of 3.77 and a beta of 1.11. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings results on Thursday, October 24th. The medical research company reported $0.67 EPS for the quarter, hitting analysts’ consensus estimates of $0.67. The company had revenue of $1.35 billion for the quarter, compared to the consensus estimate of $1.57 billion. Edwards Lifesciences had a net margin of 70.82% and a return on equity of 20.76%. Edwards Lifesciences’s revenue was up 8.9% on a year-over-year basis. During the same period in the previous year, the firm earned $0.59 EPS. Analysts forecast that Edwards Lifesciences Co. will post 2.56 EPS for the current year.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.